Skip to main content
18 Jan 2022
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
Read More
8 Jan 2022
3 Jan 2022
21 Dec 2021
16 Dec 2021
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial
Read More
10 Dec 2021
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
Read More
3 Dec 2021
3 Dec 2021
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care
Read More
2 Dec 2021
UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease
Read More
30 Nov 2021
UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
Read More
Subscribe to
